You + Our Million Dollar 2x Match Challenge = 2x the Impact
You + Our Million Dollar 2x Match Challenge = 2x the Impact
Help us fight Alzheimer’s and deliver twice the help and hope during our Million Dollar 2x Match Challenge. Your gift will advance research and help provide care and support for the millions affected by Alzheimer’s.
Donate NowAlzheimer’s Association Statement on FDA Complete Response Letter for Donanemab
CHICAGO, January 19, 2023 — The Alzheimer’s Association appreciates the Food and Drug Administration’s (FDA) methodical process in reviewing treatments for Alzheimer’s disease. The FDA’s determination that additional data is required to reach a decision on accelerated approval of donanemab (Lilly) demonstrates the rigorous approach the agency takes in reviewing individual treatments.
The donanemab Phase 2 Alzheimer’s trial showed significant slowing of decline on a measure of memory, thinking and daily function in people living with early Alzheimer’s, compared to placebo.
On behalf of our constituents, we look forward to the Phase 3 trial topline data read-out expected later this year, and the outcome of ongoing discussions between the company and the FDA.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.
The first survivor of Alzheimer's is out there, but we won't get there without you.
Donate Now
Learn how Alzheimer’s disease affects the brain.
Take the Brain Tour